{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:14:14Z","timestamp":1791249254541,"version":"4.1.0"},"reference-count":0,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2002,8,1]],"date-time":"2002-08-01T00:00:00Z","timestamp":1028160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World j. surg."],"published-print":{"date-parts":[[2002,8]]},"abstract":"Population\u2010based screening showed 2.1% prevalence of primary hyperparathyroidism (pHPT) in postmenopausal women. Individuals with total serum (s)\u2010calcium levels of 2.55\u00a0mmol\/L or more at screening were diagnosed with pHPT when subsequent analysis supported inappropriately elevated intact parathormone (PTH) levels in relation to even normal s\u2010calcium levels. The arbitrary diagnostic criteria were validated by parathyroidectomy. Herein we reinvestigated biochemical signs of pHPT in women not diagnosed with pHPT due to s\u2010calcium 2.50 to 2.54\u00a0mmol\/L (group A, n = 160) at screening or due to appropriate PTH levels on two occasions after screening (group B, n = 70). Altogether, 99 women in group A and 47\u00a0in group B underwent reinvestigation 8.8 years after screening when they were 65 to 84 years old. The s\u2010calcium levels averaged 2.56\u00a0mmol\/L and had increased in group A (mean 0.04\u00a0mmol\/L) and decreased in group B (mean 0.05\u00a0mmol\/L). A total of 48 and 18 females (48%, 38%), respectively, met the previously validated criteria of pHPT. Altogether 21% of them were hypercalcemic (range 2.60\u20133.12\u00a0mmol\/L). Subgroup analysis showed that PTH had not increased with time (n = 47) and that atherogenic blood lipids, but not glucose levels, were similar in pHPT patients and matched controls (n = 37). Assuming the existence of pHPT already at screening, the prevalence of pHPT could be adjusted to 3.4%. Even the most liberal diagnostic criteria utilized at pHPT screening seemed to underdiagnose the disease by inefficient cutoff limits for s\u2010calcium and PTH. Because one\u2010fifth of the women with pHPT progressed to hypercalcemia, long\u2010term follow\u2010up is advocated for those with s\u2010calcium in the upper normal range.<\/jats:p>","DOI":"10.1007\/s00268-002-6621-0","type":"journal-article","created":{"date-parts":[[2002,10,14]],"date-time":"2002-10-14T12:45:16Z","timestamp":1034599516000},"page":"931-936","source":"Crossref","is-referenced-by-count":88,"title":["Primary Hyperparathyroidism Revisited in Menopausal Women with Serum Calcium in the Upper Normal Range at Population\u2010based Screening 8 Years Ago"],"prefix":"10.1002","volume":"26","author":[{"given":"Ewa","family":"Lundgren","sequence":"first","affiliation":[{"name":"Endocrine Unit Department of Surgery University Hospital S\u2010751 85 Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil G.","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[{"name":"Endocrine Unit Department of Surgery University Hospital S\u2010751 85 Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Lundin","sequence":"additional","affiliation":[{"name":"Endocrine Unit Department of Surgery University Hospital S\u2010751 85 Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajsa","family":"Winnerb\u00e4ck","sequence":"additional","affiliation":[{"name":"Endocrine Unit Department of Surgery University Hospital S\u2010751 85 Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Roos","sequence":"additional","affiliation":[{"name":"Endocrine Unit Department of Surgery University Hospital S\u2010751 85 Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sverker","family":"Ljunghall","sequence":"additional","affiliation":[{"name":"AstraZeneca R&D S\u2010431 83 M\u00f6lndal Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Rastad","sequence":"additional","affiliation":[{"name":"Endocrine Unit Department of Surgery University Hospital S\u2010751 85 Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,8]]},"container-title":["World Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00268-002-6621-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00268-002-6621-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1007\/s00268-002-6621-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T15:17:57Z","timestamp":1703690277000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1007\/s00268-002-6621-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["10.1007\/s00268-002-6621-0"],"URL":"https:\/\/doi.org\/10.1007\/s00268-002-6621-0","archive":["Portico"],"relation":{},"ISSN":["0364-2313","1432-2323"],"issn-type":[{"value":"0364-2313","type":"print"},{"value":"1432-2323","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8]]}}}